255 related articles for article (PubMed ID: 14668077)
1. Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?
David SP; Niaura R; Papandonatos GD; Shadel WG; Burkholder GJ; Britt DM; Day A; Stumpff J; Hutchison K; Murphy M; Johnstone E; Griffiths SE; Walton RT
Nicotine Tob Res; 2003 Dec; 5(6):935-42. PubMed ID: 14668077
[TBL] [Abstract][Full Text] [Related]
2. Effect of nicotine lozenges on affective smoking withdrawal symptoms: secondary analysis of a randomized, double-blind, placebo-controlled clinical trial.
Shiffman S
Clin Ther; 2008 Aug; 30(8):1461-75. PubMed ID: 18803988
[TBL] [Abstract][Full Text] [Related]
3. The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood.
Cinciripini P; Wetter D; Tomlinson G; Tsoh J; De Moor C; Cinciripini L; Minna J
Nicotine Tob Res; 2004 Apr; 6(2):229-39. PubMed ID: 15203796
[TBL] [Abstract][Full Text] [Related]
4. How does bupropion work as a smoking cessation aid?
Warner C; Shoaib M
Addict Biol; 2005 Sep; 10(3):219-31. PubMed ID: 16109583
[TBL] [Abstract][Full Text] [Related]
5. Neurocognitive variation in smoking behavior and withdrawal: genetic and affective moderators.
Evans DE; Park JY; Maxfield N; Drobes DJ
Genes Brain Behav; 2009 Feb; 8(1):86-96. PubMed ID: 19220487
[TBL] [Abstract][Full Text] [Related]
6. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
Lerman C; Jepson C; Wileyto EP; Epstein LH; Rukstalis M; Patterson F; Kaufmann V; Restine S; Hawk L; Niaura R; Berrettini W
Neuropsychopharmacology; 2006 Jan; 31(1):231-42. PubMed ID: 16123753
[TBL] [Abstract][Full Text] [Related]
7. Bupropion for the treatment of nicotine withdrawal and craving.
Mooney ME; Sofuoglu M
Expert Rev Neurother; 2006 Jul; 6(7):965-81. PubMed ID: 16831112
[TBL] [Abstract][Full Text] [Related]
8. Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers.
Sofuoglu M; Babb D; Hatsukami DK
Nicotine Tob Res; 2003 Dec; 5(6):947-53. PubMed ID: 14668079
[TBL] [Abstract][Full Text] [Related]
9. Dopamine receptor genes (DRD2, DRD3 and DRD4) and gene-gene interactions associated with smoking-related behaviors.
Vandenbergh DJ; O'Connor RJ; Grant MD; Jefferson AL; Vogler GP; Strasser AA; Kozlowski LT
Addict Biol; 2007 Mar; 12(1):106-16. PubMed ID: 17407504
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse.
Covey LS; Glassman AH; Jiang H; Fried J; Masmela J; LoDuca C; Petkova E; Rodriguez K
Addiction; 2007 Aug; 102(8):1292-302. PubMed ID: 17624979
[TBL] [Abstract][Full Text] [Related]
11. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.
David SP; Strong DR; Munafò MR; Brown RA; Lloyd-Richardson EE; Wileyto PE; Evins AE; Shields PG; Lerman C; Niaura R
Nicotine Tob Res; 2007 Dec; 9(12):1251-7. PubMed ID: 18058343
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients.
De Ruyck K; Nackaerts K; Beels L; Werbrouck J; De Volder A; Meysman M; Salhi B; Van Meerbeeck J; Thierens H
Pharmacogenomics; 2010 Aug; 11(8):1053-63. PubMed ID: 20712524
[TBL] [Abstract][Full Text] [Related]
13. No evidence for a major role of polymorphisms during bupropion treatment.
Hu J; Redden DT; Berrettini WH; Shields PG; Restine SL; Pinto A; Lerman C; Allison DB
Obesity (Silver Spring); 2006 Nov; 14(11):1863-7. PubMed ID: 17135598
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of nicotine withdrawal syndrome in pilots during flight.
Giannakoulas G; Katramados A; Melas N; Diamantopoulos I; Chimonas E
Aviat Space Environ Med; 2003 Mar; 74(3):247-51. PubMed ID: 12650272
[TBL] [Abstract][Full Text] [Related]
15. Treatment of adolescent smokers with the nicotine patch.
Hanson K; Allen S; Jensen S; Hatsukami D
Nicotine Tob Res; 2003 Aug; 5(4):515-26. PubMed ID: 12959789
[TBL] [Abstract][Full Text] [Related]
16. Oxygen as a therapy for reducing nicotine withdrawal symptoms.
Granger RH
Med Hypotheses; 2005; 65(6):1161-4. PubMed ID: 16002232
[TBL] [Abstract][Full Text] [Related]
17. Heavy nicotine and alcohol use in alcohol dependence is associated with D2 dopamine receptor (DRD2) polymorphism.
Connor JP; Young RM; Lawford BR; Saunders JB; Ritchie TL; Noble EP
Addict Behav; 2007 Feb; 32(2):310-9. PubMed ID: 16766132
[TBL] [Abstract][Full Text] [Related]
18. Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials.
Shiffman S; West R; Gilbert D;
Nicotine Tob Res; 2004 Aug; 6(4):599-614. PubMed ID: 15370156
[TBL] [Abstract][Full Text] [Related]
19. The use of bupropion hydrochloride for smoking cessation therapy.
Nichols MR
Clin Excell Nurse Pract; 1999 Nov; 3(6):317-22. PubMed ID: 10865568
[TBL] [Abstract][Full Text] [Related]
20. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
Evins AE; Cather C; Culhane MA; Birnbaum A; Horowitz J; Hsieh E; Freudenreich O; Henderson DC; Schoenfeld DA; Rigotti NA; Goff DC
J Clin Psychopharmacol; 2007 Aug; 27(4):380-6. PubMed ID: 17632223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
